Abstracts tagged "osteoprotegerin"

Abstract Number: 2459 • 2014 ACR/ARHP Annual Meeting
Osteoprotegerin CGA Haplotype Protection Against Cerebrovascular Complications in Anti-CCP Negative Patients with Rheumatoid Arthritis
Fernanda Genre¹, Raquel López-Mejías¹, Mercedes García-Bermúdez², Santos Castañeda³, Carlos González-Juanatey⁴, Javier Llorca⁵, Alfonso Corrales¹, Begoña Ubilla¹, Jose A. Miranda-Filloy⁶, Encarnación Amigo⁶, Trinitario Pina Murcia¹, Carmen Gómez-Vaquero⁷, Luis Rodriguez-Rodriguez⁸, Benjamin Fernández Gutierrez⁸, Alejandro Balsa⁹, Dora Pascual-Salcedo⁹, Francisco Javier López-Longo¹⁰, Patricia Carreira¹¹, Ricardo Blanco¹², Isidoro González-Alvaro¹³, Javier Martin¹⁴ and Miguel A González-Gay¹, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ²Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ³Rheumatology, Hospital Universitario de La Princesa, IISP, Madrid, Spain, ⁴Hospital Universitario Lucus Augusti. Cardiology Division, Lugo, Spain, ⁵Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁶Hospital Universitario Lucus Augusti, Rheumatology Division, Lugo, Spain, ⁷Rheumatology Service, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, Spain, ⁸Hospital Clínico San Carlos, Department of Rheumatology, Madrid, Spain, ⁹Hospital Universitario La Paz, Department of Rheumatology, Madrid, Spain, ¹⁰Hospital General Universitario Gregorio Marañón, Department of Rheumatology, Madrid, Spain, ¹¹Hospital Universitario 12 de Octubre, Department of Rheumatology, Madrid, Spain, ¹²Hospital Marques de Valdecilla, Santander, Spain, ¹³Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁴Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain
Background/Purpose: Rheumatoid arthritis is an inflammatory disease with a high incidence of cardiovascular disease due to accelerated atherosclerosis. Osteoprotegerin (OPG) has been associated with an…
Abstract Number: 412 • 2014 ACR/ARHP Annual Meeting
Determinants of Radiological Progression in Rheumatoid Arthritis: Relationship with Serum Levels of OPG, RANKL and DKK-1
Carmen Gómez-Vaquero¹, Irene Martín-Esteve¹, Jose Ivorra², Jose Antonio Narvaez³, Javier Hernandez Gañan³, Pedro Alia⁴ and Javier Narváez⁵, ¹Rheumatology Service, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, Spain, ²Department of Rheumatology, Hospital Universitario y Politécnico La Fe., Valencia, Spain, ³Radiology Department, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, Spain, ⁴Clinical Laboratory Service, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, Spain, ⁵Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain
Background/Purpose: Osteoprotegerin (OPG), RANKL, and DKK-1 act as regulators of bone resorption and formation. The uncoupling of bone remodelling that occurs in rheumatoid arthritis (RA)…
Abstract Number: 395 • 2014 ACR/ARHP Annual Meeting
Could Osteoprotegerin and TNF-Related Apoptosis-Inducing Ligand Assessments Help Us to Manage Early Rheumatoid Arthritis? Results from the Espoir Cohort
Rachel Audo¹, Claire I. Daien², Laura Papon¹, Cédric Lukas³, O Vittecoq⁴, B Combe⁵ and Jacques Morel⁶, ¹IGMM, CNRS UMR5535, Montpellier, Montpellier, France, ²Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ³Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ⁴Rouen University Hospital & Inserm U905, Rouen, France, ⁵Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁶Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France
Background/Purpose : TNF-Related Apoptosis Inducing Ligand (TRAIL) is a member of the TNF familly. Its soluble receptor Osteoprotegerin (OPG) also inhibits Receptor activator of nuclear…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].